1,3-bis(2-chloroethyl)-1-nitrosourea enhances the inhibitory effect of Resveratrol on 5-fluorouracil sensitive/resistant colon cancer cells

World Journal of Gastroenterology

Volumn 19, Issue 42, 2013, Pages 7374-7388

  Das, Dipon ^a   Preet, Ranjan ^a   Mohapatra, Purusottam ^a   Satapathy, Shakti Ranjan ^a   Kundu, Chanakya Nath ^a  

^a KIIT UNIVERSITY   (India)

Author keywords

1,3 bis(2 chloroethyl) 1 nitrosourea; 5 fluorouracil; Colon cancer; Combination therapy; Resveratrol

Indexed keywords

CARMUSTINE; CASEIN KINASE I; CASPASE 3; CYCLIN DEPENDENT KINASE 2; CYCLINE; FLICE INHIBITORY PROTEIN; FLUOROURACIL; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P21; RESVERATROL; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE REGULATION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; G2 PHASE CELL CYCLE CHECKPOINT; GENOTOXICITY; HUMAN; HUMAN CELL; NECROSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA; 5-FLUOROURACIL; COLON CANCER; COMBINATION THERAPY; RESVERATROL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARMUSTINE; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; HCT116 CELLS; HUMANS; STILBENES;

EID: 84887593687     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i42.7374     Document Type: Article

References (63)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1991. CA Cancer J Clin 1991; 41: 19-36 [PMID: 1984806 DOI: 10.3322/ canjclin.41.1.19]
2. Glimelius B, Hoffman K, Graf W, Påhlman L, Sjödén PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994; 73: 556-562 [PMID: 8299077]
3. Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/ leucovorin alone among US elderly stage IV colon cancer patients. Cancer 2012; 118: 3173-3181 [PMID: 22020739 DOI: 10.1002/cncr.26613]
4. Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther 2011; 12: 229-238 [PMID: 21725212 DOI: 10.4161/cbt.12.3.17033]
5. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, Majumdar AP. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 2008; 122: 267-273 [PMID: 17918158 DOI: 10.1002/ijc.23097]
6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947 [PMID: 10944126]
7. Mohapatra P, Preet R, Choudhuri M, Choudhuri T, Kundu CN. 5-fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells. Oncol Res 2011; 19: 311-321 [PMID: 21936401 DOI: 10.3727/096504011X13079697 132844]
8. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A: 1263-1269 [PMID: 7999410 DOI: 10.1016/0959-8049(94)90170-8]
9. Longley DB, Latif T, Boyer J, Allen WL, Maxwell PJ, Johnston PG. The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. Semin Oncol 2003; 30: 3-9 [PMID: 12802789 DOI: 10.1016/ S0093-7754(03)00119-2]
10. Wyatt MD, Wilson DM. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009; 66: 788-799 [PMID: 18979208 DOI: 10.1007/s00018-008-8557-5]
11. Luo Y, Walla M, Wyatt MD. Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. DNA Repair (Amst) 2008; 7: 162-169 [PMID: 17942376 DOI: 10.1016/ j.dnarep.2007.09.001]
12. Li L, Connor EE, Berger SH, Wyatt MD. Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency. Biochem Pharmacol 2005; 70: 1458-1468 [PMID: 16191427 DOI: 10.1016/ j.bcp.2005.08.016]
13. Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One 2011; 6: e20849 [PMID: 21695150 DOI: 10.1371/journal. pone.0020849]
14. Scifo C, Cardile V, Russo A, Consoli R, Vancheri C, Capasso F, Vanella A, Renis M. Resveratrol and propolis as necrosis or apoptosis inducers in human prostate carcinoma cells. Oncol Res 2004; 14: 415-426 [PMID: 15490973]
15. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007; 109: 2293-2302 [PMID: 17164350 DOI: 10.1182/ blood-2006-02-003988]
16. Opipari AW, Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004; 64: 696-703 [PMID: 14744787 DOI: 10.1158/0008-5472.CAN-03-2404]
17. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, Bursch W, Camougrand N, Cebollero E, Cecconi F, Chen Y, Chin LS, Choi A, Chu CT, Chung J, Clarke PG, Clark RS, Clarke SG, Clavé C, Cleveland JL, Codogno P, Colombo MI, Coto-Montes A, Cregg JM, Cuervo AM, Debnath J, Demarchi F, Dennis PB, Dennis PA, Deretic V, Devenish RJ, Di Sano F, Dice JF, Difiglia M, Dinesh-Kumar S, Distelhorst CW, Djavaheri-Mergny M, Dorsey FC, Dröge W, Dron M, Dunn WA Jr, Duszenko M, Eissa NT, Elazar Z, Esclatine A, Eskelinen EL, Fésüs L, Finley KD, Fuentes JM, Fueyo J, Fujisaki K, Galliot B, Gao FB, Gewirtz DA, Gibson SB, Gohla A, Goldberg AL, Gonzalez R, González-Estévez C, Gorski S, Gottlieb RA, Häussinger D, He YW, Heidenreich K, Hill JA, Høyer-Hansen M, Hu X, Huang WP, Iwasaki A, Jäättelä M, Jackson WT, Jiang X, Jin S, Johansen T, Jung JU, Kadowaki M, Kang C, Kelekar A, Kessel DH, Kiel JA, Kim HP, Kimchi A, Kinsella TJ, Kiselyov K, Kitamoto K, Knecht E, Komatsu M, Kominami E, Kondo S, Kovács AL, Kroemer G, Kuan CY, Kumar R, Kundu M, Landry J, Laporte M, Le W, Lei HY, Lenardo MJ, Levine B, Lieberman A, Lim KL, Lin FC, Liou W, Liu LF, Lopez-Berestein G, López-Otín C, Lu B, Macleod KF, Malorni W, Martinet W, Matsuoka K, Mautner J, Meijer AJ, Meléndez A, Michels P, Miotto G, Mistiaen WP, Mizushima N, Mograbi B, Monastyrska I, Moore MN, Moreira PI, Moriyasu Y, Motyl T, Münz C, Murphy LO, Naqvi NI, Neufeld TP, Nishino I, Nixon RA, Noda T, Nürnberg B, Ogawa M, Oleinick NL, Olsen LJ, Ozpolat B, Paglin S, Palmer GE, Papassideri I, Parkes M, Perlmutter DH, Perry G, Piacentini M, Pinkas-Kramarski R, Prescott M, Proikas-Cezanne T, Raben N, Rami A, Reggiori F, Rohrer B, Rubinsztein DC, Ryan KM, Sadoshima J, Sakagami H, Sakai Y, Sandri M, Sasakawa C, Sass M, Schneider C, Seglen PO, Seleverstov O, Settleman J, Shacka JJ, Shapiro IM, Sibirny A, Silva-Zacarin EC, Simon HU, Simone C, Simonsen A, Smith MA, Spanel-Borowski K, Srinivas V, Steeves M, Stenmark H, Stromhaug PE, Subauste CS, Sugimoto S, Sulzer D, Suzuki T, Swanson MS, Tabas I, Takeshita F, Talbot NJ, Tallóczy Z, Tanaka K, Tanaka K, Tanida I, Taylor GS, Taylor JP, Terman A, Tettamanti G, Thompson CB, Thumm M, Tolkovsky AM, Tooze SA, Truant R, Tumanovska LV, Uchiyama Y, Ueno T, Uzcátegui NL, van der Klei I, Vaquero EC, Vellai T, Vogel MW, Wang HG, Webster P, Wiley JW, Xi Z, Xiao G, Yahalom J, Yang JM, Yap G, Yin XM, Yoshimori T, Yu L, Yue Z, Yuzaki M, Zabirnyk O, Zheng X, Zhu X, Deter RL. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151-175
18. Zamin LL, Filippi-Chiela EC, Dillenburg-Pilla P, Horn F, Salbego C, Lenz G. Resveratrol and quercetin cooperate to induce senescence-like growth arrest in C6 rat glioma cells. Cancer Sci 2009; 100: 1655-1662 [PMID: 19496785 DOI: 10.1111/j.1349-7006.2009.01215.x]
19. Jiang H, Zhang L, Kuo J, Kuo K, Gautam SC, Groc L, Rodriguez AI, Koubi D, Hunter TJ, Corcoran GB, Seidman MD, Levine RA. Resveratrol-induced apoptotic death in human U251 glioma cells. Mol Cancer Ther 2005; 4: 554-561 [PMID: 15827328 DOI: 10.1158/1535-7163.MCT-04-0056]
20. Li J, Qin Z, Liang Z. The prosurvival role of autophagy in Resveratrol-induced cytotoxicity in human U251 glioma cells. BMC Cancer 2009; 9: 215 [PMID: 19566920 DOI: 10.1186/1471-2407-9-215]
21. Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer 2011; 30: 463-471 [PMID: 21718592 DOI: 10.5732/ cjc.011.10111]
22. Panigrahi M, Das PK, Parikh PM. Brain tumor and Gliadel wafer treatment. Indian J Cancer 2011; 48: 11-17 [PMID: 21330749 DOI: 10.4103/0019-509X.76623]
23. Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 1990; 233: 117-126 [PMID: 2233793 DOI: 10.1016/0027-5107(90)90156-X]
24. Ludlum DB. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest 1997; 15: 588-598 [PMID: 9412665 DOI: 10.3109/ 07357909709047601]
25. Ludlum DB. Formation of cyclic adducts in nucleic acids by the haloethylnitrosoureas. IARC Sci Publ 1986; (70): 137-146 [PMID: 3793169]
26. Kohn KW. Interstrand cross-linking of DNA by 1,3-bis(2- chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1- nitrosoureas. Cancer Res 1977; 37: 1450-1454 [PMID: 851960]
27. Hang B, Chenna A, Guliaev AB, Singer B. Miscoding properties of 1,N6-ethanoadenine, a DNA adduct derived from reaction with the antitumor agent 1,3-bis(2-chloroethyl)-1- nitrosourea. Mutat Res 2003; 531: 191-203 [PMID: 14637255 DOI: 10.1016/j.mrfmmm.2003.07.006]
28. Kuo CC, Liu TW, Chen LT, Shiah HS, Wu CM, Cheng YT, Pan WY, Liu JF, Chen KL, Yang YN, Chen SN, Chang JY. Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. Free Radic Biol Med 2011; 51: 2195-2209 [PMID: 22001324 DOI: 10.1016/j.freeradbiomed.2011.09.023]
29. Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2- chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res 2005; 11: 7861-7865 [PMID: 16278409 DOI: 10.1158/1078-0432.CCR-05-0060]
30. Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, Brem H. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 2010; 66: 530-57discussion 537 [PMID: 20173548 DOI: 10.1227/01.NEU.0000365263.14725.39]
31. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323 [PMID: 15549093 DOI: 10.1038/nature03097]
32. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7: 2955-2966 [PMID: 18790776 DOI: 10.1158/1535-7163. MCT-08-0492]
33. Ashwell S, Zabludoff S. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008; 14: 4032-4037 [PMID: 18593978 DOI: 10.1158/1078-0432.CCR-07-5138]
34. Wilsker D, Bunz F. Loss of ataxia telangiectasia mutatedand Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther 2007; 6: 1406-1413 [PMID: 17431119 DOI: 10.1158/1535-7163. MCT-06-0679]
35. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13: 1955-1960 [PMID: 17404075 DOI: 10.1158/1078-0432. CCR-06-2793]
36. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006; 5: 1935-1943 [PMID: 16928813 DOI: 10.1158/1535-7163.MCT-06-0077]
37. de Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E, Stokke T. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol 2004; 24: 1279-1288 [PMID: 15067352]
38. Narayan S, Jaiswal AS. Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53. J Biol Chem 1997; 272: 30619-30622 [PMID: 9388195 DOI: 10.1074/ jbc.272.49.30619]
39. Jaiswal AS, Balusu R, Armas ML, Kundu CN, Narayan S. Mechanism of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision repair. Biochemistry 2006; 45: 15903-15914 [PMID: 17176113 DOI: 10.1021/ bi0607958]
40. Balusu R, Jaiswal AS, Armas ML, Kundu CN, Bloom LB, Narayan S. Structure/function analysis of the interaction of adenomatous polyposis coli with DNA polymerase beta and its implications for base excision repair. Biochemistry 2007; 46: 13961-13974 [PMID: 17999539 DOI: 10.1021/bi701632e]
41. Kundu CN, Balusu R, Jaiswal AS, Gairola CG, Narayan S. Cigarette smoke condensate-induced level of adenomatous polyposis coli blocks long-patch base excision repair in breast epithelial cells. Oncogene 2007; 26: 1428-1438 [PMID: 16924228 DOI: 10.1038/sj.onc.1209925]
42. Preet R, Mohapatra P, Mohanty S, Sahu SK, Choudhuri T, Wyatt MD, Kundu CN. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer 2012; 130: 1660-1670 [PMID: 21544805 DOI: 10.1002/ijc.26158]
43. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35: 206-221 [PMID: 10737956 DOI: 10.1002/(SICI)1098-2280(2000)35:]
44. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338 [PMID: 12724731 DOI: 10.1038/nrc1074]
45. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220 [PMID: 8985016 DOI: 10.1126/science. 275.5297.218]
46. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 2003; 23: 17-28 [PMID: 12792772]
47. Shi Y, Yang S, Troup S, Lu X, Callaghan S, Park DS, Xing Y, Yang X. Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol Rep 2011; 25: 1713-1719 [PMID: 21479363 DOI: 10.3892/or.2011.1248]
48. Miki H, Uehara N, Kimura A, Sasaki T, Yuri T, Yoshizawa K, Tsubura A. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int J Oncol 2012; 40: 1020-1028 [PMID: 22218562 DOI: 10.3892/ijo.2012.1325]
49. Zhou JH, Cheng HY, Yu ZQ, He DW, Pan Z, Yang DT. Resveratrol induces apoptosis in pancreatic cancer cells. Chin Med J (Engl) 2011; 124: 1695-1699 [PMID: 21740780 DOI: 10.3760/cma.j.issn.0366-6999.2011.11.017]
50. Yan L, Donze JR, Liu L. Inactivated MGMT by O6-benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. Oncogene 2005; 24: 2175-2183 [PMID: 15735757 DOI: 10.1038/sj.onc.1208250]
51. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]
52. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
53. Wang W, Collie-Duguid E, Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett 2002; 531: 415-420 [PMID: 12435585 DOI: 10.1016/S0014-5793(02)03575-5]
54. Zhu H, Guo W, Zhang L, Davis JJ, Teraishi F, Wu S, Cao X, Daniel J, Smythe WR, Fang B. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005; 4: 451-456 [PMID: 15767554 DOI: 10.1158/1535-7163.MCT-04-0162]
55. Wilson SH. Mammalian base excision repair and DNA polymerase beta. Mutat Res 1998; 407: 203-215 [PMID: 9653447 DOI: 10.1016/S0921-8777(98)00002-0]
56. Srivastava DK, Berg BJ, Prasad R, Molina JT, Beard WA, Tomkinson AE, Wilson SH. Mammalian abasic site base excision repair. Identification of the reaction sequence and ratedetermining steps. J Biol Chem 1998; 273: 21203-21209 [PMID: 9694877 DOI: 10.1074/jbc.273.33.21203]
57. Bambara RA, Murante RS, Henricksen LA. Enzymes and reactions at the eukaryotic DNA replication fork. J Biol Chem 1997; 272: 4647-4650 [PMID: 9081985 DOI: 10.1074/ jbc.272.8.4647]
58. Klungland A, Lindahl T. Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO J 1997; 16: 3341-3348 [PMID: 9214649 DOI: 10.1093/emboj/ 16.11.3341]
59. Narayan S, Jaiswal AS, Balusu R. Tumor suppressor APC blocks DNA polymerase beta-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J Biol Chem 2005; 280: 6942-6949 [PMID: 15548520 DOI: 10.1074/jbc.M409200200]
60. Jaiswal AS, Narayan S. p53-dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents. J Biol Chem 2001; 276: 18193-18199 [PMID: 11279192 DOI: 10.1074/jbc.M101298200]
61. Horton JK, Wilson SH. Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair (Amst) 2007; 6: 530-543 [PMID: 17113833 DOI: 10.1016/j.dnarep.2006.10.016]
62. Hu HY, Horton JK, Gryk MR, Prasad R, Naron JM, Sun DA, Hecht SM, Wilson SH, Mullen GP. Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping. J Biol Chem 2004; 279: 39736-39744 [PMID: 15258144 DOI: 10.1074/jbc.M402842200]
63. Beard WA, Wilson SH. Structure and mechanism of DNA polymerase Beta. Chem Rev 2006; 106: 361-382 [PMID: 16464010 DOI: 10.1021/cr0404904]